[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fBNdNqsUXWH8DDertEtQ9W-rcR6GAx4eCZUfFZwv6Kcg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":32,"phaseBuckets":48,"rows":55},"University of Luebeck",[4],75,false,13,3,52296,63,[13,16,19,21,23,25,27,30],{"name":14,"count":15},"Atrial Fibrillation",6,{"name":17,"count":18},"Infertility",4,{"name":20,"count":9},"Heart Failure",{"name":22,"count":9},"Coronary Artery Disease",{"name":24,"count":9},"Pregnancy",{"name":26,"count":9},"Acute Myocardial Infarction",{"name":28,"count":29},"Atrial Fibrillation (AF)",2,{"name":31,"count":29},"Spatial Neglect",[33,38,43],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT05279560","Ovarian PRP (Platelet Rich Plasma) Injection for Follicular Activation","2025-04-30","autologous PRP",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05173597","Real-world Evidence on Follitropin Delta Individual Dosing","2026-03","Follitropin delta",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT07389941","Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation","2029-04","Semaglutide",[49,50,51,52,53,54],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[56,79,105,127,155,173,200,218,236,254,280,307,325,350,375,411],{"intervention":47,"totalTrials":57,"cells":58},1,{"EARLY_PHASE1":59,"PHASE1":62,"PHASE2":64,"PHASE3":66,"PHASE4":68,"NA":77},{"trials":60,"activeCount":61},[],0,{"trials":63,"activeCount":61},[],{"trials":65,"activeCount":61},[],{"trials":67,"activeCount":61},[],{"trials":69,"activeCount":57,"soonestReadout":46},[70],{"nctId":44,"briefTitle":45,"status":71,"phases":72,"primaryCompletion":46,"completion":46,"start":73,"enrollment":74,"conditions":75,"interventions":76},"NOT_YET_RECRUITING",[53],"2026-10",240,[28],[47],{"trials":78,"activeCount":61},[],{"intervention":37,"totalTrials":57,"cells":80},{"EARLY_PHASE1":81,"PHASE1":83,"PHASE2":85,"PHASE3":87,"PHASE4":89,"NA":91},{"trials":82,"activeCount":61},[],{"trials":84,"activeCount":61},[],{"trials":86,"activeCount":61},[],{"trials":88,"activeCount":61},[],{"trials":90,"activeCount":61},[],{"trials":92,"activeCount":57,"soonestReadout":36},[93],{"nctId":34,"briefTitle":35,"status":94,"phases":95,"primaryCompletion":36,"completion":96,"start":97,"enrollment":98,"conditions":99,"interventions":104},"ACTIVE_NOT_RECRUITING",[54],"2030-06-30","2022-03-17",114,[100,101,102,103],"Premature Ovarian Insufficiency","Infertility, Female","Sterility, Female","PRP",[37],{"intervention":42,"totalTrials":57,"cells":106},{"EARLY_PHASE1":107,"PHASE1":109,"PHASE2":111,"PHASE3":113,"PHASE4":115,"NA":117},{"trials":108,"activeCount":61},[],{"trials":110,"activeCount":61},[],{"trials":112,"activeCount":61},[],{"trials":114,"activeCount":61},[],{"trials":116,"activeCount":61},[],{"trials":118,"activeCount":57,"soonestReadout":41},[119],{"nctId":39,"briefTitle":40,"status":120,"phases":121,"primaryCompletion":41,"completion":41,"start":122,"enrollment":123,"conditions":124,"interventions":126},"RECRUITING",[],"2021-12-08",850,[17,125],"Sterility",[42],{"intervention":128,"totalTrials":57,"cells":129},"MMF (Cellcept) and Steroids",{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":136,"PHASE4":138,"NA":153},{"trials":131,"activeCount":61},[],{"trials":133,"activeCount":61},[],{"trials":135,"activeCount":61},[],{"trials":137,"activeCount":61},[],{"trials":139,"activeCount":61},[140],{"nctId":141,"briefTitle":142,"status":143,"phases":144,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":151},"NCT00912678","Minimizing Immunosuppression in Old for Old Kidney Transplantation","COMPLETED",[53],"2006-07","2008-10","2002-03",90,[150],"Kidney Transplantation",[128,152],"Tacrolimus",{"trials":154,"activeCount":61},[],{"intervention":152,"totalTrials":57,"cells":156},{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":165,"NA":171},{"trials":158,"activeCount":61},[],{"trials":160,"activeCount":61},[],{"trials":162,"activeCount":61},[],{"trials":164,"activeCount":61},[],{"trials":166,"activeCount":61},[167],{"nctId":141,"briefTitle":142,"status":143,"phases":168,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":169,"interventions":170},[53],[150],[128,152],{"trials":172,"activeCount":61},[],{"intervention":174,"totalTrials":57,"cells":175},"Morphinhydrochloricum",{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":180,"PHASE3":182,"PHASE4":184,"NA":198},{"trials":177,"activeCount":61},[],{"trials":179,"activeCount":61},[],{"trials":181,"activeCount":61},[],{"trials":183,"activeCount":61},[],{"trials":185,"activeCount":61},[186],{"nctId":187,"briefTitle":188,"status":143,"phases":189,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":194},"NCT02627950","Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction",[53],"2018-10","2015-12",138,[26],[174,195,196,197],"Metoclopramide","Ticagrelor","Isotonic sodium chloride",{"trials":199,"activeCount":61},[],{"intervention":195,"totalTrials":57,"cells":201},{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":206,"PHASE3":208,"PHASE4":210,"NA":216},{"trials":203,"activeCount":61},[],{"trials":205,"activeCount":61},[],{"trials":207,"activeCount":61},[],{"trials":209,"activeCount":61},[],{"trials":211,"activeCount":61},[212],{"nctId":187,"briefTitle":188,"status":143,"phases":213,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":214,"interventions":215},[53],[26],[174,195,196,197],{"trials":217,"activeCount":61},[],{"intervention":196,"totalTrials":57,"cells":219},{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":228,"NA":234},{"trials":221,"activeCount":61},[],{"trials":223,"activeCount":61},[],{"trials":225,"activeCount":61},[],{"trials":227,"activeCount":61},[],{"trials":229,"activeCount":61},[230],{"nctId":187,"briefTitle":188,"status":143,"phases":231,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":232,"interventions":233},[53],[26],[174,195,196,197],{"trials":235,"activeCount":61},[],{"intervention":197,"totalTrials":57,"cells":237},{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":252},{"trials":239,"activeCount":61},[],{"trials":241,"activeCount":61},[],{"trials":243,"activeCount":61},[],{"trials":245,"activeCount":61},[],{"trials":247,"activeCount":61},[248],{"nctId":187,"briefTitle":188,"status":143,"phases":249,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":250,"interventions":251},[53],[26],[174,195,196,197],{"trials":253,"activeCount":61},[],{"intervention":255,"totalTrials":57,"cells":256},"Glycoprotein IIb\u002FIIIa inhibitors",{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":263,"PHASE4":265,"NA":278},{"trials":258,"activeCount":61},[],{"trials":260,"activeCount":61},[],{"trials":262,"activeCount":61},[],{"trials":264,"activeCount":61},[],{"trials":266,"activeCount":61},[267],{"nctId":268,"briefTitle":269,"status":270,"phases":271,"primaryCompletion":272,"completion":273,"start":274,"enrollment":275,"conditions":276,"interventions":277},"NCT02739711","Glycoprotein IIb\u002FIIIa Inhibitors Versus Standard Therapy in Patients with Myocardial Infarction and No-reflow","UNKNOWN",[53],"2024-05","2025-12","2016-07",120,[26],[255],{"trials":279,"activeCount":61},[],{"intervention":281,"totalTrials":57,"cells":282},"adrenaline",{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":287,"PHASE3":289,"PHASE4":303,"NA":305},{"trials":284,"activeCount":61},[],{"trials":286,"activeCount":61},[],{"trials":288,"activeCount":61},[],{"trials":290,"activeCount":61},[291],{"nctId":292,"briefTitle":293,"status":143,"phases":294,"primaryCompletion":295,"completion":296,"start":297,"enrollment":298,"conditions":299,"interventions":301},"NCT00446017","The Effects of Adrenaline and Milrinone in Patients With Myocardial Dysfunction After CABG",[52],"2004-08","2007-04","2003-06",60,[300],"Cardiac Output, Low",[281,302],"milrinone",{"trials":304,"activeCount":61},[],{"trials":306,"activeCount":61},[],{"intervention":302,"totalTrials":57,"cells":308},{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":315,"PHASE4":321,"NA":323},{"trials":310,"activeCount":61},[],{"trials":312,"activeCount":61},[],{"trials":314,"activeCount":61},[],{"trials":316,"activeCount":61},[317],{"nctId":292,"briefTitle":293,"status":143,"phases":318,"primaryCompletion":295,"completion":296,"start":297,"enrollment":298,"conditions":319,"interventions":320},[52],[300],[281,302],{"trials":322,"activeCount":61},[],{"trials":324,"activeCount":61},[],{"intervention":326,"totalTrials":57,"cells":327},"Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine",{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":344,"PHASE4":346,"NA":348},{"trials":329,"activeCount":61},[],{"trials":331,"activeCount":61},[],{"trials":333,"activeCount":61},[334],{"nctId":335,"briefTitle":336,"status":143,"phases":337,"primaryCompletion":338,"completion":338,"start":339,"enrollment":340,"conditions":341,"interventions":343},"NCT00656656","Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus",[51],"2011-07","2008-01",23,[342],"Pemphigus",[326],{"trials":345,"activeCount":61},[],{"trials":347,"activeCount":61},[],{"trials":349,"activeCount":61},[],{"intervention":351,"totalTrials":57,"cells":352},"liraglutide",{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":367,"PHASE3":369,"PHASE4":371,"NA":373},{"trials":354,"activeCount":61},[],{"trials":356,"activeCount":61},[357],{"nctId":358,"briefTitle":359,"status":143,"phases":360,"primaryCompletion":361,"completion":361,"start":362,"enrollment":363,"conditions":364,"interventions":366},"NCT01550653","Liraglutide Effects on Memory in Healthy Subjects",[50],"2013-12","2012-05",40,[365],"Healthy",[351],{"trials":368,"activeCount":61},[],{"trials":370,"activeCount":61},[],{"trials":372,"activeCount":61},[],{"trials":374,"activeCount":61},[],{"intervention":376,"totalTrials":29,"cells":377},"Lucentis",{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":384,"PHASE4":386,"NA":388},{"trials":379,"activeCount":61},[],{"trials":381,"activeCount":61},[],{"trials":383,"activeCount":61},[],{"trials":385,"activeCount":61},[],{"trials":387,"activeCount":61},[],{"trials":389,"activeCount":61},[390,402],{"nctId":391,"briefTitle":392,"status":143,"phases":393,"primaryCompletion":394,"completion":395,"start":396,"enrollment":397,"conditions":398,"interventions":401},"NCT01269151","Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD",[54],"2013-03","2014-04","2010-10",20,[399,400],"Age-Related Macular Degeneration","Retinal Function",[376],{"nctId":403,"briefTitle":404,"status":143,"phases":405,"primaryCompletion":406,"start":407,"enrollment":408,"conditions":409,"interventions":410},"NCT01638858","Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)",[54],"2014-07","2011-10",25,[399],[376],{"intervention":412,"totalTrials":57,"cells":413},"0.5mg intraocular Ranibizumab",{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":420,"PHASE4":422,"NA":424},{"trials":415,"activeCount":61},[],{"trials":417,"activeCount":61},[],{"trials":419,"activeCount":61},[],{"trials":421,"activeCount":61},[],{"trials":423,"activeCount":61},[],{"trials":425,"activeCount":61},[426],{"nctId":427,"briefTitle":428,"status":143,"phases":429,"primaryCompletion":430,"completion":338,"start":431,"enrollment":397,"conditions":432,"interventions":435},"NCT01370135","Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma",[54],"2011-04","2008-11",[433,434],"Neovascular Glaucoma","Rubeosis",[412]]